61.   This performance follows similar surges in U.S. biotechnology stocks after positive test results from several U.S. companies apparently prompted new optimism in the sector.

62.   This year, biotechnology stocks have continued to lag behind the market, with the smallest companies generally the weakest performers.

63.   Two-thirds of its assets are in networking and semiconductor companies, digital hardware makers and biotechnology stocks.

64.   With biotechnology stocks falling, there seemed little chance of raising money by selling more shares to the public.

65.   Prices turned mixed on Wall Street on Tuesday as biotechnology stocks pulled the Nasdaq composite index lower and Dow stocks wavered in response to a big acquisition by Alcoa.

66.   Prices were mostly lower on Wall Street today as biotechnology stocks pulled the Nasdaq composite index lower and blue chips wavered following a big acquisition announcement by Alcoa.

67.   And biotechnology stocks continued their most recent winning streak.

68.   An analyst at S.G. Cowen reiterated a strong buy rating on Pharmacopia and range of other biotechnology stocks.

69.   And biotechnology stocks continued their most winning streak.

70.   Biotechnology stocks were also up across-the board.